Vives Fund

Promethera Biosciences treats first patients with Promethera® HepaStem

admin — Mon, 14 May 2012 13:36:32 +0000

Mont-Saint-Guibert, Belgium, May 14 2012 – Promethera Biosciences, a Belgian biotechnology Company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem). These patients were treated and are followed at the Cliniques Universitaires Saint-Luc (Brussels, Belgium).

Continue reading →

Vives subscribes to a € 6 million capital increase to support GreenWatt growth

admin — Fri, 20 Apr 2012 15:53:31 +0000

Vives – Louvain Technology Fund subscribes jointly with historic shareholders and new investors Gimv Agri+, RWE Innogy Ventures and SRIW to a € 6 million capital increase of GreenWatt S.A. With this capital increase, GreenWatt S.A. will accelerate its international development in the waste-to-energy business.

Continue reading →

Launch of VivesII, the largest european university technology fund

admin — Wed, 28 Sep 2011 08:49:55 +0000

Louvain-la-Neuve, 28 September 2011 - The Université catholique de Louvain (UCL) and Sopartec, its technology transfer company, today announced the launch of Vives II. The first financing round, which brings together a dozen investors, amounts to €43 million, making Vives II the largest European investment fund ever initiated by a university.

Click on the link below to download our press release in a PDF format.

Press release in a PDF format

Continue reading →